{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T07:30:47Z","timestamp":1768894247512,"version":"3.49.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,8]]},"DOI":"10.1182\/bloodadvances.2023009658","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T22:13:23Z","timestamp":1684361603000},"page":"3932-3935","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Is aggressive treatment of smoldering myeloma the path to curing myeloma?"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-3003","authenticated-orcid":false,"given":"Rajshekhar","family":"Chakraborty","sequence":"first","affiliation":[{"name":"1Multiple Myeloma and Amyloidosis Program, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[{"name":"2Myeloma Section, Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5977-907X","authenticated-orcid":false,"given":"Edward R.","family":"Scheffer Cliff","sequence":"additional","affiliation":[{"name":"3Program on Regulation, Therapeutics and Law, Brigham and Women's Hospital, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-783X","authenticated-orcid":false,"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Huntsman Cancer Center, University of Utah, Salt Lake City, UT"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"issue":"2","key":"2023080716345886700_bib1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","article-title":"Prevalence of smoldering multiple myeloma based on nationwide screening","volume":"29","author":"Thorsteinsd\u00f3ttir","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"2023080716345886700_bib2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2023080716345886700_bib3","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2023080716345886700_bib4","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1182\/blood-2022-159606","article-title":"Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): post-hoc analysis of sustained undetectable measurable residual disease (MRD)","volume":"140","author":"Mateos","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023080716345886700_bib5","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood-2022-168930","article-title":"Fixed duration therapy with daratumumab, carfilzomib, lenalidomide and dexamethasone for high risk smoldering multiple myeloma-results of the ascent trial","volume":"140","author":"Kumar","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2023080716345886700_bib6","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/jamaoncol.2021.3971","article-title":"Carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance for prevention of symptomatic multiple myeloma in patients with high-risk smoldering myeloma: a phase 2 nonrandomized controlled trial","volume":"7","author":"Kazandjian","year":"2021","journal-title":"JAMA Oncol"},{"issue":"11","key":"2023080716345886700_bib7","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1080\/10428194.2021.1938032","article-title":"The landscape\u00a0of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt","volume":"62","author":"Mohyuddin","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2023080716345886700_bib8","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1182\/blood.2021011670","article-title":"How I approach smoldering multiple myeloma","volume":"140","author":"Vaxman","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2023080716345886700_bib9","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"2023080716345886700_bib10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International myeloma working group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"2023080716345886700_bib11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jamaoncol.2020.5585","article-title":"Assessment of discordance among smoldering multiple myeloma risk models","volume":"7","author":"Hill","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"2023080716345886700_bib12","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","article-title":"Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study","volume":"10","author":"Cowan","year":"2023","journal-title":"Lancet Haematol"},{"issue":"6","key":"2023080716345886700_bib13","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1111\/bjh.18102","article-title":"Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials","volume":"197","author":"Soomro","year":"2022","journal-title":"Br J Haematol"},{"key":"2023080716345886700_bib14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejca.2022.05.041","article-title":"Survival in smouldering myeloma and symptomatic myeloma: is there an emerging Will Rogers phenomenon?","volume":"172","author":"Chakraborty","year":"2022","journal-title":"Eur J Cancer"},{"issue":"7","key":"2023080716345886700_bib15","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2023080716345886700_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"issue":"6","key":"2023080716345886700_bib17","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"2023080716345886700_bib18","doi-asserted-by":"crossref","first-page":"e210048","DOI":"10.1148\/rycan.2021210048","article-title":"Prospective evaluation of whole-body MRI versus FDG PET\/CT for lesion detection in participants with myeloma","volume":"3","author":"Messiou","year":"2021","journal-title":"Radiol Imaging Cancer"},{"issue":"6","key":"2023080716345886700_bib19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1200\/JCO.2014.57.9961","article-title":"Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement","volume":"33","author":"Dimopoulos","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2023080716345886700_bib20","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus\u00a0pomalidomide and dexamethasone for patients with relapsed or\u00a0refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol"},{"issue":"9","key":"2023080716345886700_bib21","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"2023080716345886700_bib22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","article-title":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","volume":"24","author":"Mina","year":"2023","journal-title":"Lancet Oncol"},{"issue":"6","key":"2023080716345886700_bib23","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol"},{"issue":"12","key":"2023080716345886700_bib24","doi-asserted-by":"crossref","first-page":"e892","DOI":"10.1016\/S2352-3026(20)30292-1","article-title":"Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review","volume":"7","author":"Chakraborty","year":"2020","journal-title":"Lancet Haematol"},{"issue":"15","key":"2023080716345886700_bib25","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.21.02810","article-title":"The time toxicity of cancer treatment","volume":"40","author":"Gupta","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023080716345886700_bib26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-022-00671-z","article-title":"Financial toxicity in hematological malignancies: a systematic review","volume":"12","author":"Ouchveridze","year":"2022","journal-title":"Blood Cancer J"},{"issue":"29","key":"2023080716345886700_bib27","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023080716345886700_bib28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bjh.18232","article-title":"Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damage","volume":"199","author":"Wennmann","year":"2022","journal-title":"Br J Haematol"},{"issue":"11","key":"2023080716345886700_bib29","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41408-021-00569-2","article-title":"Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis","volume":"11","author":"Visram","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"2023080716345886700_bib30","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/s41467-021-22140-0","article-title":"Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities","volume":"12","author":"Oben","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"2023080716345886700_bib31","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","author":"Bolli","year":"2018","journal-title":"Nat Commun"},{"issue":"3","key":"2023080716345886700_bib32","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jamaoncol.2019.4659","article-title":"Moving from cancer burden to cancer genomics for smoldering myeloma: a review","volume":"6","author":"Maura","year":"2020","journal-title":"JAMA Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/15\/3932\/2069690\/blooda_adv-2023-009658-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/15\/3932\/2069690\/blooda_adv-2023-009658-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T16:35:23Z","timestamp":1691426123000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/15\/3932\/495857\/Is-aggressive-treatment-of-smoldering-myeloma-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":32,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,8,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023009658","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]}}}